NCT03813992已完成3 期
A Phase III, Dose Ranging, Multi-centre, Randomised, Double Blind, Placebo Controlled, Home Use, Parallel Group Clinical Trial of Topically-applied Glyceryl Trinitrate for the Treatment of Erectile Dysfunction, With an Open Label Extension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,005
- 试验地点
- 53
- 主要终点
- International Index for Erectile Function (IIEF) Questionnaire
研究概览
简要总结
To demonstrate the efficacy of various doses of MED2005 versus placebo in male patients with clinically diagnosed erectile dysfunction, and to evaluate the long-term efficacy and safety (12 months) of MED2005.
详细描述
A phase III, dose-ranging, multi-centre, randomised, double-blind, placebo controlled , home-use, parallel group clinical trial of topically applied glyceryl trinitrate for the treatment of erectile dysfunction with an open label extension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject is a male aged between 18 and 70 years inclusive, at screening
- •Confirmed clinical diagnosis of ED for more than 3 months according to the NIH Consensus Statement ('the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance at least once')
- •Subject answers 'yes' to the question regarding the presence of residual EF over the past 3 months: 'At home over the past 3 months, have you experienced at least some growth of your penis in response to: (1) mechanical stimulation by yourself or your partner, or (2) visual stimulation?'
- •Subject has been involved in a continuous heterosexual relationship for at least 6 months prior to screening
- •Documented written informed consent from both subject and his female partner
- •If the male subject's female partner is of childbearing potential from the time of first sexual intercourse attempt during the screening period until the last administration of study treatment, then the couple must have been using a medically acceptable form of contraception for at least 3 months prior to entering the study, and agree to continue such use for at least 1 month after the last study drug administration. Subjects who are or wish to become pregnant will not be included in the study.
- •Subject and his female partner are capable of understanding and complying with the requirements of the protocol and must have signed the ICF prior to participation in any study related procedures
- •Low IIEF-EF scores (≤ 25) during the screening period
- •To continue in the open-label extension phase of the study, subjects must meet the following inclusion criteria at the follow-up visit of the double-blind phase (Visit 6):
- •Subject and his female partner complete the double-blind phase
- •Subject and his female partner were compliant to study procedures during the double blind phase
- •Documented written informed consent from both subject and his female partner
- •If the male subject's female partner is of childbearing potential from the time of first sexual intercourse attempt during the screening period until the last administration of study treatment, then the couple must have been using a medically acceptable form of contraception for at least 3 months prior to entering the study, and agree to continue such use for at least 1 month after the last study drug administration. Subjects who are or wish to become pregnant will not be included in the study.
排除标准
- •Any significant or serious cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease which, in the opinion of the PI, renders the subject unfit to take part in the study
- •Subject has any history of an unstable medical or psychiatric condition or using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study Certain concomitant medications; e.g. other vasodilators, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, beta blockers, diuretics, anti hypertensives, tricyclic anti depressants and major tranquillisers, as well as the consumption of alcohol, may potentiate the BP lowering effects of MED2005; therefore, the PI must consider this carefully and include subjects at their discretion
- •Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or their delegate at screening or during the study
- •Any presence of chronic indwelling urethral catheterisation or penile anatomical abnormalities (e.g. penile fibrosis) that would significantly impair EF
- •Any history of operations for Peyronie's disease
- •Primary hypoactive sexual desire or any history of hypogonadism
- •Any history of radical prostatectomy
- •Any history of severe/uncontrolled diabetes
- •Subjects taking two or more anti hypertensives for the treatment of BP
- •Hypersensitivity to GTN or to any of the excipients, or idiosyncratic reactions to other organic nitrates
- •Concomitant treatment with sildenafil citrate, tadalafil, vardenafil and other PDE 5 inhibitors
- •Subjects taking Alpha blockers
- •Subjects receiving testosterone pellets
- •Any penile surgery except circumcision
- •Any treatment with acetyl cysteine within 6 months
- •Any treatment with dihydroergotamine within 6 months
- •Postural hypotension, hypotension or uncorrected hypovolaemia, as the use of GTN in such states could produce severe hypotension or shock
- •Increased intracranial pressure (e.g. head trauma or cerebral haemorrhage) or inadequate cerebral circulation
- •Any history of migraine or recurrent headache
- •Aortic or mitral stenosis
- •Hypertrophic obstructive cardiomyopathy
- •Constrictive pericarditis or pericardial tamponade
- •Closed-angle glaucoma
- •Subjects with nursing partners, known pregnant partners or with partners who wish to become pregnant during the course of the study
- •Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone) or from the alcohol breath test at screening (for clarification, any positive result from the urine drug screen or alcohol breath tests at screening will mean the subject will be excluded from the study). In the instance that a subject is using medication which may give a positive result, exclusion will be at the PI's discretion
- •Subject has recent (last 12 months) clinical evidence of alcoholism or drug abuse.
- •Subject has a positive screen for hepatitis B, consisting of hepatitis B surface antigen (HBsAG), hepatitis C antibody, and human immunodeficiency virus (HIV)
- •Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission
- •Subjects unwilling to cease use of vacuum devices, intracavernosal injections, PDE-5s or other therapy for ED for the entire course of the study
- •Unwillingness of the subject or their partner to agree to make the required attempts at sexual intercourse during treatment period
- •Any history of unresponsiveness to PDE 5 treatment or significant side effects, excluding visual disturbances, with PDE 5s
- •Fewer than four attempts at sexual intercourse during the screening period
- •Subjects or their partners who are illiterate or are unable to understand the language in which the questionnaires are available
- •Subject has received any investigational product during the 90 days prior to dosing for this study
- •Subject or his partner cannot communicate reliably with the PI
- •Subjects with severe premature ejaculation (little or no control of ejaculation at the time of penetration)
- •Subjects are prohibited from participating in the open-label extension phase of the study if they meet any of the following exclusion criteria at the follow-up visit of the double-blind phase (Visit 6):
- •Subsequent to recruitment into the double-blind phase of the study, the development of any significant or serious cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease which, in the opinion of the PI, renders the subject unfit to continue in the open-label extension phase of the study
- •Subject using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete or participate in the open-label phase of the study.
- •NB The concomitant medications listed as exclusion criteria for the study apply to the open-label extension phase. Certain concomitant medications; e.g. other vasodilators, calcium channel blockers, ACE inhibitors, beta blockers, diuretics, anti hypertensives, tricyclic anti depressants and major tranquillisers, as well as the consumption of alcohol, may potentiate the BP lowering effects of MED2005; therefore, the PI must consider this carefully and include subjects at their discretion
- •Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or their delegate at the start of the open-label extension phase
- •Subsequent to recruitment into the double-blind phase of the study, the development of postural hypotension, hypotension or uncorrected hypovolaemia, increased intracranial pressure or inadequate cerebral circulation, any clinically significant vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at Visit 6 prior to recruitment to the open-label phase
研究组 & 干预措施
MED2005 0.6%
Active Comparator
MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
干预措施: MED2005 (Drug)
MED2005 0.2%
Active Comparator
MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
干预措施: MED2005 (Drug)
MED2005 0.4%
Active Comparator
MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
干预措施: MED2005 (Drug)
Placebo vehicle
Placebo Comparator
Placebo vehicle applied topically prior to a sexual intercourse attempt
干预措施: MED2005 (Drug)
结局指标
主要结局
International Index for Erectile Function (IIEF) Questionnaire
时间窗: Up to Week 64 of the study
A questionnaire containing 15 questions divided into 5 domains; erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.
Sexual Encounter Profile (SEP) Questionnaire (Question 2)
时间窗: Up to Week 64 of the study
A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.
Sexual Encounter Profile (SEP) Questionnaire (Question 3)
时间窗: Up to Week 64 of the study
A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.
次要结局
- Global Assessment Questionnaire (GAQ)(Up to Week 12 of the study.)
- Sexual Encounter Profile (SEP) Questionnaire (Questions 1, 4 & 5)(Up to Week 64 of the study.)
- Self-Esteem and Relationship (SEAR) Questionnaire(Up to Week 12 of the study.)
- International Index for Erectile Function (IIEF) Questionnaire (additional domains)(Up to Week 64 weeks of the study.)
- Patient Global Impression of Severity (PGI-S)(Up to Week 12 of the study.)
- Patient Global Impression of Change (PGI-C)(Up to Week 12 of the study)
- Usage and application(Up to Week 12 of the study)
- Sexual Encounter Profile (SEP) Questionnaire(Up to Week 64 of the study)
- Onset and duration of action (erection) and erection hardness(Up to Week 12 of the study)
研究者
研究点 (53)
Loading locations...
相似试验
已完成
3 期
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected PatientsHepatitis C, ChronicNCT01292239Janssen Pharmaceutical K.K.183
已完成
3 期
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaPathological MyopiaNCT01217944Novartis Pharmaceuticals277
已完成
3 期
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17Attention Deficit Disorder With HyperactivityNCT00150618Shire324
已完成
3 期
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous TherapyHepatitis CNCT01281839Janssen R&D Ireland394
已完成
3 期
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected PatientsHepatitis CNCT01289782Janssen R&D Ireland395